Canada Spends Logo

Explore our Budget 2026 analysis

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

Université de Montréal

$120,000.00

Characterizing CD57+CD8+ T Cells in the Periphery and in the Central Nervous System of Aging People with Multiple Sclerosis

FY 2025-26

Summary
Multiple sclerosis (MS) is a disease where the immune system attacks the brain and spinal cord, leading to inflammation and damage. More than 90,000 Canadians live with MS. The disease can appear in two main stages: an early stage, and a later "progressive" stage where disability steadily worsens. Aging is the main risk factor for MS becoming progressive. While treatments exist for the early stage, there are still very few effective options for the progressive stage. As we age, the immune system also ages-a process called immunosenescence. This makes the immune system less effective at defending the body, while also creating more harmful inflammation. A type of immune cell called CD8 T cells can carry a marker of this aging process, known as CD57. These "aged" CD8 T cells are found in higher numbers in people with progressive MS and in those who have never received treatment. Our project aims to understand why these aged CD8 T cells are harmful and whether they carry other markers that could be targeted with new therapies. To do this, we will study both the proteins and the genetic activity (mRNA) of these cells in the blood and brains of people with MS, comparing younger and older patients as well as healthy individuals. Distinct protein or mRNA levels that appear in CD8 T cells from older MS patients, but not in younger or healthy individuals, could point us toward new treatment strategies for progressive MS, where they are urgently needed.
Program
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
559351
Name
Calderaro Margherita L
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Characterizing CD57+CD8+ T Cells in the Periphery and in the Central Nervous System of Aging People with Multiple Sclerosis
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Aging; Central Nervous System; Flow-Cytometry; Human Samples; Immunosenescence; Inflammation; Multiple Sclerosis; Peripheral Blood Mononuclear Cells; Single Cell Rna Sequencing; T Cells
Abstract
Multiple sclerosis (MS) is a disease where the immune system attacks the brain and spinal cord, leading to inflammation and damage. More than 90,000 Canadians live with MS. The disease can appear in two main stages: an early stage, and a later "progressive" stage where disability steadily worsens. Aging is the main risk factor for MS becoming progressive. While treatments exist for the early stage, there are still very few effective options for the progressive stage. As we age, the immune system also ages-a process called immunosenescence. This makes the immune system less effective at defending the body, while also creating more harmful inflammation. A type of immune cell called CD8 T cells can carry a marker of this aging process, known as CD57. These "aged" CD8 T cells are found in higher numbers in people with progressive MS and in those who have never received treatment. Our project aims to understand why these aged CD8 T cells are harmful and whether they carry other markers that could be targeted with new therapies. To do this, we will study both the proteins and the genetic activity (mRNA) of these cells in the blood and brains of people with MS, comparing younger and older patients as well as healthy individuals. Distinct protein or mRNA levels that appear in CD8 T cells from older MS patients, but not in younger or healthy individuals, could point us toward new treatment strategies for progressive MS, where they are urgently needed.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Calderaro, Margherita L
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~
Université de Montréal - $120,000 Grant (2025-26) | Canada Spends